WallStSmart

AstraZeneca PLC (AZN)vsThe Joint Corp (JYNT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 106448% more annual revenue ($62.38B vs $58.55M). AZN leads profitability with a 17.7% profit margin vs 6.5%. AZN appears more attractively valued with a PEG of 1.35. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

JYNT

Hold

49

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 6/9Altman Z: 0.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.3%)

Margin of Safety

+4.3%

Fair Value

$197.94

Current Price

$184.45

$13.49 discount

UndervaluedFair: $197.94Overvalued

Intrinsic value data unavailable for JYNT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

JYNT3 strengths · Avg: 9.3/10
EPS GrowthGrowth
653.0%10/10

Earnings expanding 653.0% YoY

Return on EquityProfitability
20.9%9/10

Every $100 of equity generates 21 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

JYNT4 concerns · Avg: 2.8/10
Market CapQuality
$106.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.5%3/10

6.5% margin — thin

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

PEG RatioValuation
8.832/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : JYNT

The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : JYNT

The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 53.6x leaves little room for execution misses.

Key Dynamics to Monitor

AZN profiles as a mature stock while JYNT is a value play — different risk/reward profiles.

JYNT carries more volatility with a beta of 1.16 — expect wider price swings.

JYNT is growing revenue faster at 14.4% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 49/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

The Joint Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Joint Corp. The company is headquartered in Scottsdale, Arizona.

Visit Website →

Want to dig deeper into these stocks?